271 results about "Pharmaceutical Excipient" patented technology

The invention relates to the technical field of biological medicine, in particular to a ferroptosis inhibition type phospholipid-like material and application thereof. The ferroptosis inhibition type phospholipid-like material is one of the following structural general formulas (1)-(5). The biomimetic phospholipid-like ferroptosis inhibitor has a long retention characteristic in main positions (cell membranes, endoplasmic reticulum and other organelle membranes) of cell ferroptosis, so that the ferroptosis inhibition efficiency is remarkably improved. The novel phospholipid-like material not only can be used as an active drug molecule, but also can be used as a pharmaceutic adjuvant for constructing drug delivery carriers such as lipidosome and micelle and implant coatings, and is suitable for various administration routes such as oral administration, injection and local administration. The novel biomimetic ferroptosis inhibitor can efficiently relieve cell ferroptosis and has a wide application prospect in the field of treating or retarding ferroptosis-related diseases.

Provided herein are pharmaceutical compositions comprising a compound of having Formula I as described in this disclosure, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutical excipients, wherein the composition is in a unit dosage form; and methods for treating cancer modulated by HER2 in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition or a compound having Formula II as described in this disclosure, or a pharmaceutically acceptable salt thereof, and optionally one or more additional therapeutic agents.

Provided is a compound of formula I, X-Y (I) wherein: Y comprises a peptide fragment of formula IV, [Ala] m-[Lys-V]n-Lys-V (IV) in which m represents 0 or 1, n represents an integer 0, 1, 2, 3 or 4 and, each V independently represents a 2 to 4 amino acids sequence, in which the amino acids are selected from one or more of the group Lys, Pro, Hyp, diHyp, Thr, pThr, DOPA, Tyr, and Ser; and X represents at least one optional substituent selected from: (i)a lipid, which lipid is selected from the group consisting of vitamin A, vitamin E, cholesterol and a fatty acid; and / or (ii)a non-steroidal anti-inflammatory drug, which compounds are useful in medicine, including as pharmaceutical excipients, adhesives and film-forming materials and / or are useful in the treatment of conditions characterised by inflammation, including wounds, burns, and disorders of the mucosa, such as skin diseases, oral diseases, gynecological diseases and IBDs.

The invention belongs to the technical field of biological fermentation, and particularly relates to a preparation method and application of a high-activity antioxidant product based on hericium erinaceus-hawthorn solid state fermentation. Activating the strain to prepare a seed solution; adding hawthorn into the rice solid culture medium, inoculating hericium erinaceus, performing constant-temperature culture, drying a fermentation product to constant weight at normal temperature and normal pressure after the culture is finished, crushing, and sieving for later use. The antioxidant effect of the fermentation product is comprehensively evaluated and verified through a systematic in-vitro chemical antioxidant experiment (ABTS < + >, DPPH free radical and hydroxyl free radical scavenging) and an in-vivo zebra fish oxidative stress model, and solid data support is provided for application of the fermentation product in healthy products. The resource high-value utilization way of the hawthorn and the hericium erinaceus is widened, and a technical scheme and a product prototype are provided for developing novel food raw materials, health-care products or medicine auxiliary materials with definite antioxidant functions.

Disclosed in the present invention are a preparation method for a brain-targeting agomelatine nasal spray micelle and use thereof, which belong to the technical field of pharmaceutical formulations. According to the present invention, an injectable pharmaceutical excipient polyethylene glycol (15)-hydroxystearate (HS15) is taken as a carrier material, HS15 and agomelatine are dissolved in an organic solvent, and the resulting solution is subjected to rotary evaporation under reduced pressure to form a uniform film, which, upon hydration, forms an agomelatine micelle solution capable of being sprayed nasally for treating depression and insomnia. According to the present invention, the problem of low oral bioavailability of agomelatine due to poor solubility, serious first pass effect of hepar, difficulty in penetrating a blood-brain barrier, etc., is solved. The micelle structure constructed in the present invention is quickly delivered into the brain after nasal administration, and it is stable in cerebrospinal fluid and can achieve slow release of the drug, thereby improving the intracerebral bioavailability of the drug and achieving high brain targeting property and low systemic toxic and side effects. The micelle structure has good clinical application value and market prospects.

The present invention relates to a computer-implemented method for preparing multiple dosage forms with personalised composition, comprising the following steps:(i) a control unit generates an input protocol of a personalised composition of a multiple dosage form, containing information about the type and amount of individual active substances, the type of cartridge, and the type and number of capsules;(ii) a cartridge of the required type according to the input protocol, labelled with a specific machine-readable code, is placed in the automatic transport system;(iii) at least two different types of sub-units are placed into at least two dosing stations, the sub-unit having sizes in the range of from 0.1 to 4 mm, and containing a different active ingredient and / or different amounts of the same active ingredient and / or having coatings with different solubility and / or possibly containing different pharmaceutical excipients according to the input protocol;(iv) a pre-defined number of capsule bodies is placed in the cartridge placed in an automatic transport system;(v) the automatic transport system transports the cartridge with capsules to the first dosing station, which doses a pre-defined number of the first sub-units into the capsule bodies placed in the cartridge;(vi) the automatic transport system transports the cartridge with capsules to the next dosing station, which doses a pre-defined number of the next sub-units into the capsule bodies placed in the cartridge; and this step is repeated according to the input protocol until the capsules are filled with all of the pre-defined types of sub-units;(vii) the capsules are closed with caps;(viii) the quality control of capsules and discarding of the non-compliant ones;(ix) packaging and labelling with a batch number.The present invention further relates to a device for carrying out this method.

The invention provides a briracetam sustained-release pharmaceutical composition as well as a preparation method and application thereof. The pharmaceutical composition comprises a pharmaceutical active ingredient and a pharmaceutical excipient, wherein the pharmaceutical excipient is selected from one or more of a framework material, a disintegrating agent, a swelling agent, an adhesive, a filler and a lubricant. The briracetam sustained-release pharmaceutical composition disclosed by the invention is good in sustained-release effect, stable in release speed and small in side effect, the medicine taking frequency is reduced, and the compliance of a patient is improved; the retention time of the medicine in the stomach is prolonged, so that the medicine is continuously released in the stomach and is absorbed at the upper end of the small intestine, the effect of continuously taking effect for 24 hours is achieved, the plasma concentration is stable, and the adverse reaction is small; a patient is prevented from randomly interrupting medication, and disease relapse and malignant complication development are prevented; the medicine is few in administration times, convenient to take and small in toxic and side effects.

A pharmaceutical composition or a pharmaceutical preparation, the pharmaceutical composition or the pharmaceutical preparation comprising a therapeutically effective amount of an active ingredient M and a pharmaceutical excipient, the active ingredient M being selected from a compound of general formula (I) or a stereoisomer, a tautomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or eutectic thereof, the pharmaceutical composition or the pharmaceutical preparation comprises 1-600 mg of an active ingredient M. The invention also relates to application of the pharmaceutical composition or the pharmaceutical preparation in preparation of related medicines for treating cancers.

The invention belongs to the field of pharmaceutical preparations. The invention relates to a novel dosage form of an isavuconazole sulfate freeze-dried tablet, and a prescription and a process for preparing the isavuconazole sulfate freeze-dried tablet by adopting a freeze-drying method. The isavuconazole sulfate freeze-dried tablet is prepared from isavuconazole sulfate serving as a main drug and pharmaceutic adjuvants. Water is not needed during taking, and the tablet can be rapidly disintegrated after being put in the mouth and is suitable for patients with dysphagia such as old people and children; the production process of the isavuconazole sulfate freeze-dried orally disintegrating tablet is simple in technology, easy to control and suitable for industrial production.

This invention discloses an energy-saving control system for drying equipment based on multidimensional factor analysis, belonging to the field of intelligent control technology. The system includes: interactively obtaining the pre-drying material characteristics of the pharmaceutical excipients to be dried; pre-constructing a material drying optimization space; locating initial drying control parameters; obtaining multiple sets of equipment parameter adjustment values ​​mapped to multiple drying stages; performing drying simulations on the pharmaceutical excipients to be dried using stage moisture content as a constraint, obtaining multiple sets of drying times, multiple sets of equipment energy consumption, and multiple sets of excipient loss rates; obtaining a target drying control array; and running the drying equipment to perform low-energy drying of the pharmaceutical excipients to be dried. This invention solves the technical problems of existing energy-saving control systems for drying equipment, which rely on fixed parameters and are difficult to accurately match the changes in the characteristics of different pharmaceutical excipients, leading to increased energy consumption and insufficient drying quality and efficiency of pharmaceutical excipients. It achieves the technical effects of effectively reducing energy consumption, improving drying efficiency, and enhancing product quality stability.

The invention provides a probiotic fermentation and bacterial powder compound addition chewable tablet and a preparation method thereof, and belongs to the technical field of microorganisms, the preparation method comprises the following steps: respectively adding water into apple peel, cerasus humilis fruits and aronia melanocarpa fruits, pulping, and mixing in proportion to obtain mixed fruit pulp; a mixed bacterium solution of lactobacillus plantarum LNJ-HQ-01 and lactobacillus fermentum BNCC194390 is added into the mixed fruit pulp, and fermentation is performed; freeze-drying and grinding the fermented fruit pulp to obtain freeze-dried fruit powder; the preparation method comprises the following steps: respectively activating lactobacillus plantarum LNJ-HQ-01, lactobacillus acidophilus BNCC186447 and lactobacillus rhamnosus ATCC7469, performing enlarged culture, taking bacterial sludge, uniformly mixing the bacterial sludge with a freeze-drying protective additive, and performing freeze-drying to obtain freeze-dried bacterial powder; and uniformly mixing the fruit powder, the freeze-dried bacterial powder and the medicinal auxiliary materials, and tabletting to obtain the probiotic chewable tablets. The probiotic chewable tablet is high in dietary fiber content, effective calcium content and total phenol content, high in oxidation resistance and suitable for calcium supplement of special groups such as diabetics and the like.

The invention relates to the technical field of analytical chemistry detection, in particular to a method for determining trace nitrite in pharmaceutic adjuvants.The method comprises the steps that an acetonitrile solution, a potassium hydroxide solution, a phosphate buffer solution, a sulfuric acid solution, a 2, 3-diaminonaphthalene solution and a reference substance working solution are provided; the method comprises the following steps: preparing a standard curve solution and a test sample solution, and carrying out ultra-high performance liquid chromatography-tandem mass spectrometry analysis detection: respectively carrying out sample injection detection on the test sample solution and the prepared standard curve solutions with different concentrations under preset chromatographic conditions and mass spectrometry conditions, recording detection results of the standard curve solutions with different concentrations to make a standard curve, and calculating the content of nitrite in the test solution by adopting a standard addition method according to the standard curve and the detection result of the test solution. The method disclosed by the invention can be used for rapidly determining trace nitrite in a drug sample, and can be used for determining the trace nitrite in pharmaceutical adjuvants and detecting the nitrite in drugs.

Described herein is a computer-implemented method for training a machine learning model for predicting one or more physiochemical properties of a nanoparticle. In some instances, the method includes receiving a set of data including nanoparticles, generating a descriptor and fingerprint for each nanoparticle in the set of data, creating a plurality of sets of training data and a plurality of sets of test data, training a machine learning model of an artificial intelligence (AI) system using the plurality of sets of training data, and predicting a property of the drug-excipient pair of the plurality of sets of test data based on drug-excipient pairs and property values of each drug-excipient pair of the plurality of sets of training data. Also described herein are excipients conjugated to a polyethylene glycol moiety, or pharmaceutically acceptable salts thereof. In some instances, the excipients may be used to form nanoparticles with a therapeutic compound.

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

The invention discloses an aromatic propionic acid derivative as well as a preparation method, a pharmaceutical composition and application thereof. The invention specifically discloses a compound shown in a formula (I) or pharmaceutically acceptable salt thereof. The invention further discloses a pharmaceutical composition which comprises the compound shown in the formula (I), pharmaceutically acceptable salt of the compound and pharmaceutic adjuvants. The invention also discloses application of the compound as shown in the formula (I), the pharmaceutically acceptable salt of the compound or the pharmaceutical composition in preparation of drugs, and the drugs have GPR40 receptor agonistic activity and have one or more of the advantages of good activity, high targeting property, low toxicity and the like. # imgabs0 #

This utility model discloses a drying and sealing storage chamber for pharmaceutical excipients, including a chamber body and a storage rack. The top of the chamber body has two slots, each with a drying frame inserted into its inner side. Each drying frame has an opening at its top and a movable plate is detachably connected via bolts. The left and right drying frames are fixedly connected by a lifting frame. Two partitions are fixedly connected to the inner side of the chamber body, each partition having three ventilation slots on its surface. A fan is installed inside each ventilation slot. This utility model, by providing a detachable drying frame at the top of the chamber body, combined with the lifting frame, allows for complete removal and replacement of the desiccant without opening the chamber body. This avoids external environmental interference with the internal drying process. Compared to traditional fixed drying structures, it achieves flexible switching between drying and ventilation, improving operational efficiency.

The present invention relates to a pharmaceutical composition containing alkynyl compound, a preparation method thereof and its application. The present invention discloses a pharmaceutical composition comprising an active pharmaceutical ingredient and an available pharmaceutical excipient; The active pharmaceutical ingredient is 3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-benzamide, or its pharmaceutical acceptable salt; The available pharmaceutical excipients includes diluents and lubricants. The pharmaceutical composition can effectively improve the bioavailability of the alkynyl compound, has good dissolution and stability, and improve the drug safety.

The utility model discloses novel crushing equipment for medicinal auxiliary material production, which comprises a crushing box, the inner wall of the crushing box is respectively and rotatably connected with two crushing rollers, the two crushing rollers can oppositely rotate to crush auxiliary materials, one side of the crushing box is fixedly connected with a crushing motor, and the other side of the crushing box is fixedly connected with the crushing motor. The output end of the smashing motor penetrates through the inner wall of the smashing box and is fixedly connected with the smashing rollers, two sets of brushes corresponding to the smashing rollers are arranged on the inner wall of the smashing box, each brush comprises a mounting base arranged on the inner wall of the smashing box, and bristles are fixedly connected to the surfaces of the mounting bases; the bristles are attached to the smashing rollers to brush off auxiliary materials attached to the surfaces of the smashing rollers. According to the novel crushing equipment for producing the pharmaceutical excipients, the brushes are arranged, when the two crushing rollers rotate to crush the excipients, the bristles brush off the excipients attached to the surfaces of the crushing rollers, waste is reduced, and therefore the novel crushing equipment for producing the pharmaceutical excipients has the effect of reducing waste of the excipients.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a minoxidil external preparation composition as well as a preparation method and application thereof. The invention provides a minoxidil external preparation composition. The minoxidil external preparation composition comprises minoxidil, finasteride, pharmaceutic adjuvants, organic acid, ethanol and water. By adding finasteride and pharmaceutic adjuvants, the treatment effect on alopecia is enhanced; by adding a proper amount of organic acid, the dissolution of minoxidil can be promoted in the absence of propylene glycol, so that the problem of replacing a propylene glycol solvent is solved. The minoxidil external composition prepared by the invention is stable, the treatment effect of the minoxidil external composition on alopecia is obviously higher than that of a solution only containing a minoxidil single component, and the minoxidil external composition does not contain a propylene glycol component, so that the occurrence of propylene glycol allergy is avoided. And the preparation method is simple, stable and good in reproducibility.

A tizanidine liquid preparation and use of the tizanidine liquid preparation in the preparation of a medicament for treating muscle spasm, wherein the tizanidine liquid preparation comprises an active ingredient, a stabilizing agent and other pharmaceutical excipients, wherein the active ingredient is one or more of tizanidine or a pharmaceutically acceptable salt, solvate and hydrate thereof.

The invention discloses a carrier cooperation system, application and a preparation method of a dihydrocodeine tartrate tablet, the carrier cooperation system comprises a mesoporous silica carrier and a hydroxypropyl trimethyl ammonium chloride chitosan modification layer, the surface of the mesoporous silica carrier is modified by silicon hydroxyl, and the hydroxypropyl trimethyl ammonium chloride chitosan modification layer is adsorbed in a pore channel of mesoporous silica. A mesoporous silica carrier modified by hydroxypropyl trimethyl ammonium chloride chitosan is formed; the silicon hydroxyl of the mesoporous silica carrier and the carboxyl of the active pharmaceutical ingredient form a hydrogen bond, and the quaternary ammonium group of the hydroxypropyl trimethyl ammonium chloride chitosan modified layer and the active pharmaceutical ingredient containing the tertiary amine group form an electrostatic complexing effect; according to the application of the carrier synergistic system in preparation of the abuse-preventing dihydrocodeine tartrate tablet, the tablet contains the carrier synergistic system, 6.67%-10.0% of dihydrocodeine tartrate and pharmaceutic adjuvants; the invention further discloses a specific preparation method, and the double effects of abuse prevention and slow release are synchronously achieved.

The application discloses a NO donor type ligustrazine derivative, a preparation method, a composition and application, and provides a NO donor type ligustrazine derivative and a preparation method thereof, and further provides a composition of different dosage forms prepared by mixing the NO donor type ligustrazine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical excipient, and application of the composition in preparation of a medicine for preventing or treating thromboembolic cardiovascular and cerebrovascular diseases and diseases caused by platelet aggregation.

According to the device for preparing and transferring the sterile liquid medicine, a preparation assembly is used for preparation and sterile treatment of auxiliary materials of the sterile liquid medicine, and the preparation assembly is arranged in a non-sterile environment; the first batching tank is used for preparing main raw materials of the sterile liquid medicine, is arranged in a sterile environment and is connected with the preparation assembly; the second batching tank is movably arranged in a non-sterile environment, the interior of the second batching tank is in a sterile state, and the second batching tank is connected with the first batching tank; the power source device can generate power, so that the sterile liquid medicine auxiliary materials enter the first batching tank after being subjected to configuration and sterile treatment, and carry the sterile liquid medicine main raw materials in the first batching tank to enter the second batching tank; the second mixing tank can be moved to a position close to the filling line and is in sterile butt joint with the filling line. According to the device, continuous supply of materials among different clean environments can be ensured, meanwhile, flexible matching in the sterile liquid medicine preparation process is achieved, and the sterility of the materials can be kept.

A fully dissolvable anticaries remineralization toothpaste for children and a preparation method thereof. The toothpaste has a three-layer composite structure: a dissolvable backing protective layer, an anticaries remineralization active layer, and a pH responsive layer. All components are food grade or pharmaceutical excipient grade, and completely dissolve within 10-30 minutes in the oral environment, without the need to remove after use. The active layer contains a "fluoride-nano hydroxyapatite-xylitol" ternary synergistic system, which can inhibit demineralization, promote remineralization, and inhibit cariogenic bacteria. The active layer also contains pH-responsive food colorants, which visually indicate the end of use through color changes. Formulas are designed for children aged 3-6 and 6-12, respectively, and the toothpaste can be cut along the preset line to fit different arch sizes. The invention solves the problems of poor use compliance, high risk of swallowing, and short residence time of active ingredients in existing children's anticaries products, and achieves safe, effective, and fun oral care for children.

The invention provides a medicine containing dronedarone. The medicine is used for targeted inhibition of stearoyl-CoA desaturase 1 (SCD1). The main component of the medicine is dronedarone or a pharmaceutically acceptable salt thereof, and the dronedarone or the pharmaceutically acceptable salt thereof is specifically combined with an SCD1 enzyme active site to inhibit the synthesis activity of catalyzing monounsaturated fatty acid and reduce the expression level of SCD1 protein in tumor cells, so that the dronedarone or the pharmaceutically acceptable salt thereof plays a role. According to the preparation method, dronedarone and pharmaceutic adjuvants are combined to prepare an oral preparation or an injection preparation, the oral preparation contains a quick release layer and a slow release layer, and the injection preparation is a freeze-dried powder injection. The optimization scheme comprises the steps of adjusting daily administration dosage (50-400mg) and using a specific carrier. Clinical application shows that dronedarone can significantly inhibit breast cancer cell proliferation and induce cell apoptosis, has a significant effect on treatment of fatty acid metabolism disorder diseases and proliferative diseases, and provides a new way for treatment of related diseases.

The present invention provides a traditional Chinese medicine taste-masking composition, which solves the contradiction between the large volume of traditional Chinese medicine compound preparations and the low drug loading of cyclodextrin, improves the taste-masking effect while reducing the amount of excipients used, and achieves synergistic effect. The traditional Chinese medicine taste-masking composition includes sulfobutyl-β-cyclodextrin and hydroxypropyl-β-cyclodextrin, and the mass ratio is 1:1. The composition also contains methyl-β-cyclodextrin and α-cyclodextrin; or it also contains polymerized-β-cyclodextrin, cationic-β-cyclodextrin, and methyl-β-cyclodextrin. The above-mentioned cyclodextrin and its derivatives are used as pharmaceutical excipients with low production costs and are suitable for industrial promotion. In addition, the present invention also provides the use of the traditional Chinese medicine taste-masking composition in Lanqin oral preparations. Compared with the commercially available Lanqin granules, the bitterness value of the Lanqin granules prepared by the present invention is reduced by 27% to 48%, and the Lanqin granules provided by the present invention have good hygroscopicity and stable quality.

The invention belongs to the technical field of medicines, and particularly relates to compound tylosin ophthalmic gel as well as a preparation method and application thereof. The invention relates to compound tylosin ophthalmic gel. The compound tylosin ophthalmic gel is prepared from tylosin tartrate, ganciclovir, pharmaceutic adjuvants and water, the pharmaceutic adjuvants comprise a thickening agent, a filling agent, a solubilizer, a bacteriostatic agent and a pH regulator. The compound tylosin ophthalmic gel disclosed by the invention takes effect quickly, has a remarkable treatment effect on feline conjunctivitis, has a lasting curative effect, and can still keep a relatively good drug effect after drug withdrawal.

The invention relates to the technical field of compound refining and purification, in particular to a high-purity low-endotoxin pharmaceutical adjuvant sodium dihydrogen phosphate dihydrate and a preparation method thereof. Comprising the following steps: mixing industrial-grade sodium dihydrogen phosphate dihydrate with pure water to form a first solution; a heavy metal complexing agent is added into the first solution, and a second solution is formed after heating and stirring reaction; prefabricated activated carbon is added into the second solution, and a third solution is formed after heating and stirring reaction; and filtering the third solution while hot, concentrating under reduced pressure until a crystal film appears in the solution, naturally cooling and crystallizing, and performing solid-liquid separation to obtain the high-purity low-endotoxin pharmaceutical adjuvant sodium dihydrogen phosphate dihydrate. After refining and purification, the purity is greater than 99 wt%, the content of heavy metals is not greater than 0.0005 wt%, the content of endotoxin is lower than 2.5 EU / g, and the pharmaceutical adjuvant level is reached.

Disclosed in the present invention are a baicalein topical formulation and use thereof in the treatment of atopic dermatitis. The active ingredient of the formulation is baicalein, which is combined with a pharmaceutical excipient to prepare a dosage form that can be applied externally to the skin and mucous membranes. The topical formulation can be used in the treatment of atopic dermatitis and is characterized by convenience in use and significant efficacy, thereby offering broad application prospects.

The present disclosure provides high-load tablet formulations of AG10 or a pharmaceutically acceptable salt thereof. In some aspects, provided herein are table formulations of AG10 or a pharmaceutically acceptable salt thereof that include at least 40% or more AG10 by weight and at least one pharmaceutical excipient selected from one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.